A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
54actual
Sites
18
Countries
France, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-12-01 | actual | When the study began enrolling |
| Primary completion | 2025-02-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-18 | actual | The whole study's end, after follow-up |
| First posted | 2020-09-25 | actual | When this record first appeared on the registry |
| Results posted | 2024-06-25 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-08-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumours
Intervention
- Drug: Ceralasertib — also filed as AZD6738
Primary outcomes
what the primary-completion date above is the date OFCohort A (aST): Objective Response Rate (ORR).
measured 2 years 4 months
Cohort B (mCRPC): Composite Response Rate.
measured Up to 2 years 4 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-11-04 · 2.9 MB · Prot_005.pdf
Statistical Analysis Planposted 2023-01-30 · 945 KB · SAP_001.pdf
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed